Live Attenuated and Inactivated Influenza Vaccine in School-age Children

Gruber, William C.; Taber, Larry H.; Glezen, W. Paul; Clover, Richard D.; Abell, Troy D.; Demmler, Richard W.; Couch, Robert B.

doi:10.1001/archpedi.1990.02150290089035

Cited by 61 publications

(47 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…65,66 It has been shown repeatedly that seroresponse rates of antibody to HA increase with increasing age of the group immunized, ranging from 70% to 100% among adolescents. 44,46,67 Children younger than 9 years are less likely to have been primed by natural infection and thus are recommended to receive 2 doses 4 weeks apart the first season they are immunized. In one study, after 2 doses of TIV, between 89% and 91% of 6-to 24-month-old children had an HAI titer of Ն1:40 and/or a fourfold increase in antibody to influenza A(H1N1), A(H3N2), and B.…”

Section: Immunogenicity Of Tivmentioning

confidence: 99%

“…Protective efficacy against influenza illness confirmed by positive culture varies between approximately 60% and 95% when the vaccine strains match the predominant circulating strains. 44,46,64,68,76 Studies in the United States and Japan raise the possibility that immunization of schoolchildren results in diminished incidence of disease in all age groups, including the elderly. 77,78 Studies on whether influenza immunization protects against AOM have produced conflicting results.…”

Section: Efficacy Of Tivmentioning

confidence: 99%

“…The results are summarized in Table 5. The Baylor Family Study 44,67,106 enrolled 578 children between 3 and 18 years of age. The enrollment was by family, and any family remaining in the study for more than 1 year received the same treatment each year.…”

Section: Comparison Of Immunogenicity and Efficacy Of Tiv And Caiv Inmentioning

confidence: 99%

See 2 more Smart Citations

Technical Report: Reduction of the Influenza Burden in Children

Rennels¹,

Meissner²

2002

Pediatrics

View full text Add to dashboard Cite

ABSTRACT. Epidemiologic studies have shown that children of all ages with certain chronic conditions, such as asthma, and otherwise healthy children younger than 24 months (6 through 23 months) are hospitalized for influenza and its complications at high rates similar to those experienced by the elderly. Annual influenza immunization is already recommended for all children 6 months and older with high-risk conditions. By contrast, influenza immunization has not been recommended for healthy young children. To protect children against the complications of influenza, increased efforts are needed to identify and recall high-risk children. In addition, immunization of children between 6 through 23 months of age and their close contacts is now encouraged to the extent feasible. Children younger than 6 months may be protected by immunization of their household contacts and out-of-home caregivers. The ultimate goal is universal immunization of children 6 to 24 months of age.

show abstract

Section: Immunogenicity Of Tivmentioning

confidence: 99%

Section: Efficacy Of Tivmentioning

confidence: 99%

See 1 more Smart Citation

Technical Report: Reduction of the Influenza Burden in Children

Rennels¹,

Meissner²

2002

Pediatrics

View full text Add to dashboard Cite

show abstract

“…Otros síntomas reportados, generalmente leves, son: náuseas, letargia, cefalea, mialgias, calofríos. Generalmente, los eventos no han mostrado diferencias entre vacunados y quienes recibieron placebo, entre mayores y menores de 12 meses, con excepción de la fiebre, y no aumentan con la administración de dosis sucesivas [8][9][10][11][12] . Seguridad: En 250.000 niños de 6 meses a 17 años, no se observó aumento de eventos que requirieran atención médica 13 .…”

Section: Comportamiento De La Vacuna Inactivada En Niñosunclassified

Influenza: Vacunación a nuevos grupos etarios

Abarca

2007

Rev. chil. infectol.

View full text Add to dashboard Cite

Influenza: Immunization to new age groupsInfluenza immunization is a main tool to prevent this important viral illness. Traditional vaccine recommendations, mainly focused to elderly and people with chronic medical conditions, have been expanded during last years. The article summarizes the fundament of lowering the age cut off in adults and of the incorporation of healthy infants between 6 and 24 months. The performance of the vaccine in those new age groups is analyzed. Finally, new groups to possibly be incorporated in future vaccine recommendations are mentioned.Key words: Influenza; vaccine; children. . A pesar que esta recomendación implica la vacunación de un grupo importante de personas sin condiciones de riesgo, igualmente ellas tienen importante morbilidad, consultas y ausentismo laboral por influenza, lo que justifica vacunarlas.La eficacia de la vacuna en adultos entre 50 y 65 años, en condiciones en que la cepa circulante sea similar a la contenida en la vacuna, es de 70 a 90%. Un estudio realizado en la temporada 2003-04 en E.U.A. en que la cepa circulante (H3N2, cepa Fujian) fue diferente de la cepa vaccinal, con 1.055 participantes, 50% de los cuales poseían condiciones de riesgo v/s 20% en el grupo controles, se encontró una eficacia de la vacuna (definida como influenza comprobada por laboratorio) de 52% en las personas sin condiciones de riesgo y de 38% en aquellas con condiciones de riesgo 4 . Vacunación de niñosTradicionalmente, las recomendaciones de vacunación contra influenza en niños se han focalizado en aquellos con condiciones de riesgo, a partir de los 6 meses de edad (Tabla 1).Los niños presentan las mayores tasas de ataque de influenza; 15 a 42% de los pre-escolares y escolares adquieren la infección cada año, comparado con 10 a 20% en adultos. Las consultas médicas por influenza son elevadas en niños (6-29/100 niños), 3 a 5% de los a vacunación contra la influenza está recomendada, tradicionalmente, a grupos de riesgo, a saber: adultos sobre 65 años de edad, enfermos crónicos mayores de 6 meses, personal de salud y contactos de sujetos de riesgo. Hace algunos años se incorporaron las mujeres embarazadas.Más recientemente, en algunos países, se ha ampliado la recomendación de vacunación rutinaria a dos grupos etarios: adultos entre 50 y 65 años (incorporados en E.U.A. desde el año 2000) Vacunación anti-influenza en adultos entre 50 y 65 añosEste grupo etario posee una elevada prevalencia de condiciones médicas crónicas, la que sido estimada en E.U.A. en 30%. Las tasas de exceso de hospitalización en este grupo son de: 56-635/100.000 en aquellos con una o más condiciones de alto riesgo, comparada con 13-60/100.000 en los que no las presentan 3 . A pesar de tener estas condiciones médicas crónicas, y por tanto estar incluidas desde mucho tiempo en los grupos a vacunar, las coberturas en estas personas efectivamente no eran superiores a 40%. La experiencia ha enseñado que la recomendación de vacunación según grupos etarios es más eficiente que dirigirla hacia las condiciones de riesgo...

show abstract

“…7 In children under 6 years of age, approximately 40 to 80% exhibit seroconversion after a single dose of vaccine, while for children over 6 years the rate of seroconversion rises to 70 to 100%. 65,66 More than 50% of children under 3 years old and around 30% of children up to 9 years old are seronegative for the influenza virus. 67 This fact results in the recommendation to give two doses of vaccine to the 6 months to 9 years age group the first year of vaccination, with just one dose being required annually thereafter.…”

Section: Immunogenicitymentioning

confidence: 99%

Segurança, imunogenicidade e eficácia da vacina contra o vírus influenza em crianças

Cintra¹,

Rey²

2006

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

Objectives: To review the immunogenicity, safety and efficacy of inactivated and attenuated trivalent influenza vaccines in children.Sources of data: Database search of the medical literature indexed on MEDLINE, LILACS and in the Cochrane Library. Review articles, clinical trials and epidemiological studies published from 1990 to 2006 were selected for analysis. Summary of the findings:Influenza is an infectious disease that is both universal and seasonal, with incidence in all age groups and annual epidemics characterized by excessive morbidity and mortality. The elderly and people with comorbidity are high risk groups for severe influenza. It has recently been proven that healthy infants suffer similar morbidity to other risk groups, and therefore vaccination against influenza is indicated for them too, as being the most effective means of preventing infection by the influenza virus. The safety of influenza vaccines in children appears adequate, with the most often observed adverse effects being local reactions or fever. Immunogenicity in children varies from 30 to 90%, being directly proportional to age. Efficacy depends on the primary objective and can range from levels comparable with placebo to up to 91% efficacy against confirmed influenza A infection. Schoolchildren play an important role in the dissemination of the influenza virus, and population studies have demonstrated herd immunity.

show abstract

Live Attenuated and Inactivated Influenza Vaccine in School-age Children

Cited by 61 publications

References 24 publications

Technical Report: Reduction of the Influenza Burden in Children

Technical Report: Reduction of the Influenza Burden in Children

Influenza: Vacunación a nuevos grupos etarios

Segurança, imunogenicidade e eficácia da vacina contra o vírus influenza em crianças

Contact Info

Product

Resources

About